Concert Pharmaceuticals, Inc.
News
Concert Pharmaceuticals (NASDAQ:CNCE) Upgraded to "Hold" at StockNews.com
Zolmax StockNews.com upgraded shares of Concert Pharmaceuticals (NASDAQ:CNCE Get Rating) from a sell rating to a hold rating in a report released on Saturday. Other research analysts have also issued research reports about the company. Truist Financial lowered Concert Pharmaceuticals from a buy rating to a...\n more…
StockNews.com Upgrades Concert Pharmaceuticals (NASDAQ:CNCE) to "Hold"
Ticker Report Concert Pharmaceuticals (NASDAQ:CNCE Get Rating) was upgraded by research analysts at StockNews.com from a sell rating to a hold rating in a report issued on Saturday. CNCE has been the topic of a number of other reports. Truist Financial lowered shares of Concert...\n more…
Point72 Asset Management L.P. Invests $1.81 Million in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE)
Zolmax Point72 Asset Management L.P. acquired a new position in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE Get Rating) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 270,600 shares of the ...\n more…
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Short Interest Update
Ticker Report Concert Pharmaceuticals, Inc. (NASDAQ:CNCE Get Rating) saw a large decline in short interest in the month of February. As of February 15th, there was short interest totalling 1,080,000 shares, a decline of 58.5% from the January 31st total of 2,600,000 shares. Based on an average daily ...\n more…
Concert Pharmaceuticals (NASDAQ:CNCE) Downgraded by StockNews.com
Ticker Report StockNews.com lowered shares of Concert Pharmaceuticals (NASDAQ:CNCE Get Rating) from a hold rating to a sell rating in a research note published on Friday. Several other research firms also recently issued reports on CNCE. Jonestrading reiterated a hold rating on shares of Concert ...\n more…